CHPJ Articles
Showing 133–144 of 166 resultsSorted by latest
-
Coverage for new medicines in public versus private drug plans in Canada.
$0.00 Add to cart -
Fewer treatment options for patients if Canada adopts New Zealand’s prescription drug policies.
$0.00 Add to cart -
Economic cost of delayed access to 14 new cancer medicines in Canada’s public drug plans.
$0.00 Add to cart -
Including off-label drug indications in HTA jeopardizes patient health and discourages innovation
$0.00 Add to cart -
Medical Resource Availability in Canada and 34 OECD countries: 2016 Annual Report
$0.00 Add to cart -
Medical devices and health care costs in Canada and 74 other countries, 2010 to 2015
$0.00 Add to cart -
Medical Resource Availability in Canada’s Provinces: 2016 Annual Report
$0.00 Add to cart -
Pharmacare: what are the costs for patients and taxpayers?
$0.00 Add to cart -
Are cost-effectiveness rules in public drug plans denying coverage to Canadians with rare disorders?
$0.00 Add to cart -
Impact of improved data protection on health costs in Canada and Japan: lessons for the TPP.
$0.00 Add to cart -
Medical devices and health care costs in Canada and 71 other countries. 2015 Annual Report.
$0.00 Add to cart -
Economic value of the utility-expansion for new cancer drugs approved in Canada from 2004 to 2014.
$0.00 Add to cart